Vir Biotechnology, Inc.
VIR
$5.09
-$0.325-6.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.03M | 12.37M | 2.38M | 3.08M | 56.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.03M | 12.37M | 2.38M | 3.08M | 56.38M |
| Cost of Revenue | 117.62M | 88.79M | 195.23M | 105.17M | 98.53M |
| Gross Profit | -114.58M | -76.42M | -192.85M | -102.09M | -42.16M |
| SG&A Expenses | 23.94M | 26.70M | 25.74M | 30.27M | 36.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.56M | 115.49M | 220.97M | 135.43M | 134.86M |
| Operating Income | -138.53M | -103.12M | -218.59M | -132.36M | -78.48M |
| Income Before Tax | -120.95M | -104.68M | -213.54M | -139.89M | -65.00M |
| Income Tax Expenses | 16.00K | -86.00K | 177.00K | -1.51M | 276.00K |
| Earnings from Continuing Operations | -120.97M | -104.59M | -213.72M | -138.38M | -65.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.97M | -104.59M | -213.72M | -138.38M | -65.28M |
| EBIT | -138.53M | -103.12M | -218.59M | -132.36M | -78.48M |
| EBITDA | -135.66M | -100.23M | -215.70M | -128.10M | -73.96M |
| EPS Basic | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 |
| Normalized Basic EPS | -0.57 | -0.41 | -0.92 | -0.52 | -0.27 |
| EPS Diluted | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 |
| Normalized Diluted EPS | -0.57 | -0.41 | -0.92 | -0.52 | -0.27 |
| Average Basic Shares Outstanding | 137.47M | 136.81M | 136.65M | 136.23M | 135.28M |
| Average Diluted Shares Outstanding | 137.47M | 136.81M | 136.65M | 136.23M | 135.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |